Does Blue Cross Blue Shield of Michigan Cover Mounjaro?
The verdict
Conditional on most plans
Blue Cross Blue Shield of Michigan (BCN) covers Mounjaro for type 2 diabetes with prior authorization across commercial, ACA, and Medicare Part D lines. Mounjaro is not covered for weight loss under any line. BCBS Michigan is the cluster's sharpest Mounjaro vs. Zepbound case: it excludes Zepbound for weight loss — an exclusion formally upheld by the Michigan Department of Insurance and Financial Services (DIFS) in 2025. Michigan Medicaid covers weight-loss GLP-1s for on-label products (Wegovy, Zepbound) but not for Mounjaro. Verify tier on the BCN formulary.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Blue Cross Blue Shield of Michigan using your member ID.
Key facts
Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes only — not weight loss. The weight-loss tirzepatide product is Zepbound, a separate FDA approval with separate and often-excluded coverage.
FDA drug labeling, Mounjaro (tirzepatide) prescribing information
Blue Cross Blue Shield of Michigan excludes Zepbound (tirzepatide for weight loss) on commercial plans — an exclusion formally upheld by the Michigan Department of Insurance and Financial Services (DIFS) in 2025.
Michigan Department of Insurance and Financial Services (DIFS), 2025
The 2026 Medicare Part D out-of-pocket cap is $2,100; most continuous Mounjaro users for diabetes reach the cap within 2–3 months and pay $0 for the rest of the year.
CMS.gov, Medicare Part D Redesign 2025–2026
Medicare vs. commercial coverage
Whether Blue Cross Blue Shield of Michigan covers Mounjaro depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
Medicare Part D covers Mounjaro for type 2 diabetes only — not weight loss — at a specialty or non-preferred tier with prior authorization. The 2026 out-of-pocket cap is $2,100; most continuous users reach it within 2–3 months and pay $0 for the rest of the year. The IRA-negotiated Medicare MFN price of $245/month begins mid-2026. Mounjaro is NOT included in the 2026 Medicare GLP-1 Bridge ($50/month, July 1, 2026 – Dec 31, 2027), which covers weight-loss-approved products only. Lilly savings card is not usable by Medicare beneficiaries. Verify your specific BCBS Michigan Medicare plan formulary each year.
Commercial / Employer
Group & marketplace plans
Commercial and employer-sponsored BCBS Michigan plans (Blue Care Network) cover Mounjaro for type 2 diabetes with prior authorization. Mounjaro is not covered for off-label weight loss (diagnosis code E66.x). BCBS Michigan excludes Zepbound (tirzepatide, weight-loss indication) from commercial coverage — this exclusion was challenged and formally upheld by the Michigan Department of Insurance and Financial Services (DIFS) in 2025. ACA/Individual plans cover Mounjaro for T2D with PA; Zepbound weight-loss is excluded on commercial. Michigan Medicaid covers weight-loss GLP-1s (Wegovy, Zepbound) for eligible enrollees on Medicaid — but this does not apply to Mounjaro, which is diabetes-only. Commercially insured patients with coverage may pay as little as $25/month via the Lilly savings card (excludes government programs; expires 12/31/2026). Without coverage, the card reduces cost to $499/month (max $647/month, up to 13 fills). Verify tier on the BCN formulary.
The 5 boxes you must tick to get approved
Commercial plans that will consider Mounjaro require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
0 of 5 requirements selected. Meet all 5 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Mounjaro actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
Approximately $1,300–$1,560/month retail (WAC ~$1,080). Lilly savings card: $499/month for commercially insured without coverage (max $647/month, up to 13 fills; expires 12/31/2026). Excludes all government programs.
List price with no coverage — before any manufacturer savings card.
With coverage
Varies by plan tier — verify on BCN/BCBS Michigan formulary or member services. Commercially insured patients with coverage may pay as little as $25/month via the Lilly savings card.
Typical monthly copay once prior authorization is approved.
Bridge program
Lilly Mounjaro Savings Card: commercially insured patients with coverage as little as $25/mo; without coverage $499/mo (up to 13 fills, expires 12/31/2026). Not available to Medicare, Medicaid, Medicare Advantage, or government program beneficiaries.
Reduced copay through the assistance program, where eligible.
All figures are estimates; actual cost-share varies by plan tier, pharmacy, and deductible status. Confirm with BCN/BCBS Michigan formulary or member services. Medicare Part D: 25% coinsurance after deductible until the $2,100 OOP cap; MFN $245/month mid-2026. MI Medicaid nominal.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Search the Blue Care Network or BCBS Michigan formulary
Visit the BCN or BCBS Michigan member portal and use the drug lookup tool to search for 'Mounjaro' or 'tirzepatide.' Confirm the tier, prior authorization requirement, and cost-share for your specific plan type (commercial, Medicare Advantage, or Medicaid). Note that Zepbound (tirzepatide for weight loss) is separately excluded — this does not affect Mounjaro's diabetes coverage.
- 2
Have your prescriber prepare the prior authorization
Your prescriber will need to document your confirmed T2D diagnosis (ICD-10 E11.x), A1c of 6.5% or higher within about 90 days, and a trial or failure of metformin. Because BCBS Michigan's Zepbound exclusion was upheld by MI DIFS, ensure the PA is submitted with a T2D diagnosis code (E11.x) and not an obesity code (E66.x), which would be denied.
- 3
Call BCN member services if coverage is unclear
Call the member services number on the back of your BCN or BCBS Michigan card and ask: Is Mounjaro covered for type 2 diabetes on my plan? What tier? Is prior authorization required? What is my estimated cost-share? Confirm separately about Zepbound if weight loss is also a goal — it is a separate drug with separate (excluded) coverage on commercial BCN plans.
Options if Blue Cross Blue Shield of Michigan won't cover Mounjaro
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Ozempic (semaglutide)
FDA-approved for type 2 diabetes. Covered with PA across BCN/BCBS Michigan commercial and MI Medicaid plans; often placed ahead of Mounjaro in step-therapy sequences.
Trulicity (dulaglutide)
FDA-approved for T2D. GLP-1 alternative; often preferred tier with a lower list price than Mounjaro. Verify on BCN formulary.
Jardiance (empagliflozin) or Farxiga (dapagliflozin)
SGLT2 inhibitors approved for T2D with cardiovascular and renal benefits. May be part of step-therapy before GLP-1 approval on BCN/BCBS Michigan plans.
Wegovy (semaglutide) — weight loss, MI Medicaid
FDA-approved for chronic weight management. Michigan Medicaid covers weight-loss GLP-1s including Wegovy for eligible enrollees — separate from Mounjaro's diabetes coverage. Verify on MI Medicaid PDL.
Zepbound (tirzepatide) — weight loss only, MI Medicaid only
Same molecule as Mounjaro but FDA-approved for chronic weight management. BCBS Michigan excludes Zepbound on commercial plans (upheld by MI DIFS 2025). Michigan Medicaid may cover Zepbound for weight loss — a separate coverage pathway from Mounjaro's diabetes coverage.
These options are listed for information only — your own clinician decides what is appropriate for you.
Frequently Asked Questions
No. BCBS Michigan does not cover Mounjaro for weight loss. Mounjaro is FDA-approved for type 2 diabetes only. BCBS Michigan also separately excludes Zepbound (tirzepatide for weight loss) on commercial plans — an exclusion formally upheld by the Michigan Department of Insurance and Financial Services (DIFS) in 2025. Michigan Medicaid does cover weight-loss GLP-1s for on-label products, but this does not extend to Mounjaro.
In 2025, the Michigan Department of Insurance and Financial Services (DIFS) upheld BCBS Michigan's (Blue Care Network's) exclusion of Zepbound (tirzepatide for weight loss) from commercial coverage. This means patients who appealed the Zepbound weight-loss exclusion through state regulatory channels were unsuccessful. Mounjaro — the diabetes version of the same molecule — remains covered for T2D with PA, unaffected by the Zepbound exclusion ruling.
No. Michigan Medicaid covers weight-loss GLP-1s (Wegovy, Zepbound) for eligible enrollees — but this applies to the on-label weight-loss products, not Mounjaro, which is a diabetes drug. Mounjaro is covered by Michigan Medicaid for type 2 diabetes with prior authorization. Any weight-loss use of Mounjaro coded with an obesity diagnosis (E66.x) would be denied regardless of the Medicaid weight-loss GLP-1 policy.
Yes, if you have commercial BCN or BCBS Michigan coverage and Mounjaro is covered on your plan, you may pay as little as $25/month via the Lilly savings card. Without commercial coverage, the card reduces cost to $499/month (max $647/month, up to 13 fills, expires 12/31/2026). The card is not available to Medicare Part D, Medicare Advantage, MI Medicaid, or any government program beneficiaries.
No. The 2026 Medicare GLP-1 Bridge ($50/month copay, July 1, 2026 – December 31, 2027) covers weight-loss-approved products only — Wegovy, Foundayo, and the Zepbound KwikPen. Mounjaro is excluded because it is a diabetes drug. Medicare covers Mounjaro for type 2 diabetes under standard Part D with prior authorization, specialty-tier cost-share, and the $2,100 annual OOP cap.
Related Articles
Does Priority Health Cover Mounjaro? Michigan 2026 | Curex
Priority Health (MI) covers Mounjaro for T2D with prior auth — not weight loss. MI Medicaid's weight-loss GLP-1 coverage is for Zepbound, not Mounjaro.
Read moreDoes SelectHealth Cover Mounjaro? Intermountain 2026 | Curex
SelectHealth (Intermountain) covers Mounjaro for type 2 diabetes with PA — not weight loss. UT Medicaid is diabetes-only. Zepbound is the weight-loss twin.
Read moreDoes Wellcare Cover Mounjaro? Part D & Medicaid 2026 | Curex
Wellcare covers Mounjaro for type 2 diabetes under Part D and Medicaid with prior auth — not weight loss. Mounjaro is excluded from the 2026 GLP-1 Bridge.
Read moreDoes Anthem Cover Mounjaro? CarelonRx T2D Guide 2026 | Curex
Anthem covers Mounjaro for type 2 diabetes with prior auth — not weight loss. Zepbound (weight-loss tirzepatide) requires a separate employer benefit.
Read moreDoes Blue Shield of California Cover Mounjaro? 2026 | Curex
Blue Shield of California covers Mounjaro for type 2 diabetes with PA. Weight-loss GLP-1s are BMI-restricted; Medi-Cal excludes them from 2026.
Read moreDoes Blue Cross Blue Shield of Minnesota Cover Mounjaro? 2026 | Curex
BCBS of Minnesota covers Mounjaro for type 2 diabetes with PA — not weight loss. MN Medicaid covers weight-loss GLP-1s for Zepbound, not Mounjaro.
Read moreInsurance covers Mounjaro only for diabetes — for weight loss, here's a path that skips insurance
You just saw how tangled Mounjaro coverage can get — auto-rejections, prior authorization, and high cash prices. Curex compounded semaglutide: $199/month equivalent prepaid annually ($2,388 upfront), or $299/month paid monthly. Compounded tirzepatide: $299/month equivalent prepaid annually ($3,588 upfront), or $399/month paid monthly. Commercial rates as of 2026-10-12; compounded products are not FDA-approved and clinical eligibility must be assessed. Curex compounded medications are not the same as Mounjaro. No insurance or prior authorization required; prescription required, subject to provider review.
- Medication + free shipping
- 24/7 provider access
- Medical intake & prescription review
Compounded semaglutide and tirzepatide are not the same medications as Mounjaro and are not branded or FDA-approved products. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.
This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Blue Cross Blue Shield of Michigan before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation. Curex offers compounded semaglutide and tirzepatide, which are not the same medications as Mounjaro and are not branded or FDA-approved products; prescription required, subject to provider review. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.